CL2013000850A1 - Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros. - Google Patents
Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.Info
- Publication number
- CL2013000850A1 CL2013000850A1 CL2013000850A CL2013000850A CL2013000850A1 CL 2013000850 A1 CL2013000850 A1 CL 2013000850A1 CL 2013000850 A CL2013000850 A CL 2013000850A CL 2013000850 A CL2013000850 A CL 2013000850A CL 2013000850 A1 CL2013000850 A1 CL 2013000850A1
- Authority
- CL
- Chile
- Prior art keywords
- carcionoma
- mammary
- trifluoro
- morpholinyl
- pyrimidinyl
- Prior art date
Links
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 title 1
- 208000034578 Multiple myelomas Diseases 0.000 title 1
- 206010035226 Plasma cell myeloma Diseases 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 210000001072 colon Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- -1 salt monohydrochloride Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38872110P | 2010-10-01 | 2010-10-01 | |
| US201161494915P | 2011-06-09 | 2011-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000850A1 true CL2013000850A1 (es) | 2013-09-27 |
Family
ID=44773179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000850A CL2013000850A1 (es) | 2010-10-01 | 2013-03-28 | Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros. |
| CL2015001088A CL2015001088A1 (es) | 2010-10-01 | 2015-04-27 | Proceso de elaboración de compuestos derivados de pirimidina (div. sol. 850-13). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001088A CL2015001088A1 (es) | 2010-10-01 | 2015-04-27 | Proceso de elaboración de compuestos derivados de pirimidina (div. sol. 850-13). |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9181215B2 (es) |
| EP (2) | EP2621908A2 (es) |
| JP (3) | JP5998145B2 (es) |
| KR (2) | KR20180123586A (es) |
| CN (3) | CN104945373A (es) |
| AR (1) | AR083213A1 (es) |
| AU (4) | AU2011308856B2 (es) |
| BR (1) | BR112013007123B1 (es) |
| CA (1) | CA2813333C (es) |
| CL (2) | CL2013000850A1 (es) |
| CO (1) | CO6700837A2 (es) |
| DK (1) | DK3040333T3 (es) |
| EC (1) | ECSP13012596A (es) |
| ES (1) | ES2699951T3 (es) |
| GT (1) | GT201300080A (es) |
| HK (1) | HK1220686A1 (es) |
| HU (1) | HUE041326T2 (es) |
| IL (3) | IL225113A (es) |
| LT (1) | LT3040333T (es) |
| MX (1) | MX354482B (es) |
| MY (1) | MY160785A (es) |
| NZ (1) | NZ608285A (es) |
| PE (1) | PE20140002A1 (es) |
| PH (1) | PH12015501585A1 (es) |
| PL (1) | PL3040333T3 (es) |
| PT (1) | PT3040333T (es) |
| RU (2) | RU2576619C2 (es) |
| SG (1) | SG188439A1 (es) |
| SI (1) | SI3040333T1 (es) |
| TW (1) | TWI540133B (es) |
| WO (1) | WO2012044727A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA030465B1 (ru) | 2011-07-01 | 2018-08-31 | Новартис Аг | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака |
| MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| WO2014064058A1 (en) * | 2012-10-23 | 2014-05-01 | Novartis Ag | Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
| US9318944B2 (en) | 2013-04-29 | 2016-04-19 | Rockwell Automation Technologies, Inc. | Methods and apparatus for active front end filter capacitor degradation detection |
| US9294005B2 (en) | 2013-10-01 | 2016-03-22 | Rockwell Automation Technologies, Inc. | Method and apparatus for detecting AFE filter capacitor degradation |
| SG11201602446VA (en) * | 2013-10-16 | 2016-05-30 | Shanghai Yingli Pharm Co Ltd | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof |
| WO2015162084A1 (en) * | 2014-04-22 | 2015-10-29 | Universitaet Basel | Novel manufacturing process for triazine, pyrimidine and pyridine derivatives |
| CN105085476B (zh) * | 2014-11-24 | 2018-03-09 | 苏州晶云药物科技有限公司 | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法 |
| EP3235816B1 (en) | 2014-12-17 | 2020-02-12 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof |
| US9481665B2 (en) * | 2015-03-13 | 2016-11-01 | Yong Xu | Process for preparing PI3K inhibitor buparsilib |
| JP2018509448A (ja) | 2015-03-25 | 2018-04-05 | ノバルティス アーゲー | 組合せ医薬 |
| CN105001151B (zh) * | 2015-08-28 | 2017-07-14 | 苏州明锐医药科技有限公司 | 布帕尼西中间体及其制备方法 |
| CN106543140A (zh) * | 2015-09-21 | 2017-03-29 | 苏州晶云药物科技有限公司 | 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法 |
| DK3389662T3 (da) * | 2015-12-16 | 2022-02-28 | Genentech Inc | Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer |
| CN106905294A (zh) * | 2016-07-08 | 2017-06-30 | 苏州科睿思制药有限公司 | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法 |
| CN107793394A (zh) * | 2017-08-03 | 2018-03-13 | 上海厚璞生物科技有限公司 | 一种生产选择性pi3k抑制剂的系列关键中间体 |
| CN110016142B (zh) * | 2019-04-30 | 2021-08-03 | 合肥工业大学 | 一种含嘧啶硼酸结构的硅油及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124476A (en) | 1998-04-17 | 2000-09-26 | Symyx Technologies, Inc. | Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates |
| CN1735598A (zh) * | 2002-11-11 | 2006-02-15 | 拜耳医药保健股份公司 | 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物 |
| KR101052482B1 (ko) | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용 |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| AU2007287428B2 (en) | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| EP2118087B1 (en) | 2007-02-06 | 2012-03-28 | Novartis AG | Pi 3-kinase inhibitors and methods of their use |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| CA2760179A1 (en) * | 2009-05-15 | 2010-11-18 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound |
-
2011
- 2011-09-29 JP JP2013531796A patent/JP5998145B2/ja active Active
- 2011-09-29 KR KR1020187032263A patent/KR20180123586A/ko not_active Application Discontinuation
- 2011-09-29 DK DK16151719.8T patent/DK3040333T3/da active
- 2011-09-29 NZ NZ608285A patent/NZ608285A/en not_active IP Right Cessation
- 2011-09-29 MY MYPI2013000811A patent/MY160785A/en unknown
- 2011-09-29 RU RU2013120326/04A patent/RU2576619C2/ru active
- 2011-09-29 HU HUE16151719A patent/HUE041326T2/hu unknown
- 2011-09-29 CN CN201510157366.4A patent/CN104945373A/zh active Pending
- 2011-09-29 ES ES16151719T patent/ES2699951T3/es active Active
- 2011-09-29 PE PE2013000654A patent/PE20140002A1/es active IP Right Grant
- 2011-09-29 RU RU2015150728A patent/RU2015150728A/ru unknown
- 2011-09-29 US US13/825,880 patent/US9181215B2/en active Active
- 2011-09-29 MX MX2013003507A patent/MX354482B/es active IP Right Grant
- 2011-09-29 KR KR1020137011172A patent/KR20130119928A/ko active Application Filing
- 2011-09-29 LT LTEP16151719.8T patent/LT3040333T/lt unknown
- 2011-09-29 CN CN201180047753.2A patent/CN103140479B/zh active Active
- 2011-09-29 AU AU2011308856A patent/AU2011308856B2/en active Active
- 2011-09-29 PT PT16151719T patent/PT3040333T/pt unknown
- 2011-09-29 SI SI201131619T patent/SI3040333T1/sl unknown
- 2011-09-29 BR BR112013007123-0A patent/BR112013007123B1/pt active IP Right Grant
- 2011-09-29 WO PCT/US2011/053808 patent/WO2012044727A2/en active Application Filing
- 2011-09-29 CA CA2813333A patent/CA2813333C/en active Active
- 2011-09-29 EP EP11767362.4A patent/EP2621908A2/en not_active Withdrawn
- 2011-09-29 EP EP16151719.8A patent/EP3040333B1/en active Active
- 2011-09-29 SG SG2013016837A patent/SG188439A1/en unknown
- 2011-09-29 PL PL16151719T patent/PL3040333T3/pl unknown
- 2011-09-29 CN CN201510156027.4A patent/CN104987321A/zh active Pending
- 2011-09-29 AR ARP110103595A patent/AR083213A1/es unknown
- 2011-09-30 TW TW100135673A patent/TWI540133B/zh active
-
2013
- 2013-03-07 IL IL225113A patent/IL225113A/en unknown
- 2013-03-22 GT GT201300080A patent/GT201300080A/es unknown
- 2013-03-22 CO CO13057091A patent/CO6700837A2/es unknown
- 2013-03-28 CL CL2013000850A patent/CL2013000850A1/es unknown
- 2013-04-30 EC ECSP13012596 patent/ECSP13012596A/es unknown
- 2013-09-24 HK HK16108618.7A patent/HK1220686A1/zh unknown
-
2014
- 2014-06-19 IL IL233282A patent/IL233282A/en unknown
-
2015
- 2015-02-24 AU AU2015200938A patent/AU2015200938B2/en not_active Ceased
- 2015-02-24 AU AU2015200936A patent/AU2015200936A1/en not_active Abandoned
- 2015-03-30 IL IL238046A patent/IL238046A/en not_active IP Right Cessation
- 2015-04-27 CL CL2015001088A patent/CL2015001088A1/es unknown
- 2015-05-06 US US14/705,013 patent/US9359326B2/en not_active Expired - Fee Related
- 2015-07-20 PH PH12015501585A patent/PH12015501585A1/en unknown
- 2015-10-23 AU AU2015246141A patent/AU2015246141B2/en not_active Ceased
- 2015-12-17 JP JP2015246501A patent/JP2016128414A/ja active Pending
- 2015-12-17 JP JP2015246502A patent/JP2016106091A/ja active Pending
-
2016
- 2016-05-06 US US15/147,986 patent/US9452994B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000850A1 (es) | Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros. | |
| BRPI1013426A2 (pt) | organismos para produção de 1,3-butanodiol | |
| CU20170087A7 (es) | Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida | |
| CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
| FR2962442B1 (fr) | Composition stable de 2,3,3,3-tetrafluoropropene | |
| CR11019A (es) | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas | |
| JP2014501485A5 (es) | ||
| CL2014000175A1 (es) | Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. | |
| PE20140983A1 (es) | Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos | |
| CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
| ZA201404294B (en) | Substituted 1,2,5-oxadiazole compounds and their use as herbicides | |
| BRPI0822722A2 (pt) | Implemento para cuidado oral. | |
| BRPI0906802A2 (pt) | Implemento para cuidado oral. | |
| CO6880069A2 (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes | |
| ECSP10010704A (es) | Sales y polimorfos de un compuesto de tetraticlina | |
| BR112013003529A2 (pt) | "composição aerada, composição de tratamento capilar método para o tratamento capilar" | |
| JP2014530840A5 (es) | ||
| DK2773633T3 (da) | Heterocykliske forbindelser, medikamenter indeholdende forbindelserne, anvendelse deraf og fremgangsmåder til fremstilling deraf. | |
| CL2014002847A1 (es) | Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. | |
| EA201000258A1 (ru) | Новые гербициды | |
| IN2015DN01331A (es) | ||
| ES2606627T8 (es) | Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis | |
| PL3070076T3 (pl) | Związki amidowe lub ich sole, oraz ich zastosowanie jako rolnicze i ogrodnicze środki bakteriobójcze | |
| JP2013536184A5 (es) | ||
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. |